QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CAPR

QT76Capricor Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
28.38
+0.43+1.54%
OverviewShort InterestFilings
CAPRQT76Capricor Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
28.38+1.54%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.20
Insider Own37.73%
Shs Outstand57.91M
Perf Week13.34%
Market Cap1.28BForward P/E-EPS next Y-0.69Insider Trans0.43%Shs Float-Perf Month5.42%
Enterprise Value1.19BPEG0.31EPS next Q-0.58Inst Own-Short Float-Perf Quarter-8.95%
Income-91234322.00P/S0.00EPS this Y50.83%Inst Trans-Short Ratio-Perf Half Y9.07%
Sales-P/B5.76EPS next Y-17.14%ROA-35.12%Short Interest-Perf YTD-1.66%
Book/sh4.82P/C-EPS next 5Y-ROE-59.27%52W High40.37 -29.70%Perf Year132.81%
Cash/sh4.82P/FCF-EPS past 3/5Y-ROIC-40.00%52W Low4.30 560.00%Perf 3Y-
Dividend Est.-EV/EBITDA1.34Sales past 3/5Y-Gross Margin0.00%Volatility3.72% 3.34%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-101.74%Oper. Margin0.00%ATR (14)1.59Perf 10Y-
Dividend Ex-Date-Quick Ratio8.42Sales Y/Y TTM0.00%Profit Margin0.00%RSI (14)51.18Recom2.00
Dividend Gr. 3/5Y-Current Ratio8.42EPS Q/Q-11.32%SMA202.90%Beta1.95Target Price50.00
Payout0.00%Debt/Eq0.08Sales Q/Q-SMA50-7.21%Rel Volume3.01Prev Close27.95
Employees160LT Debt/Eq0.05EarningsAug 11SMA20032.72%Avg Volume1.03MPrice28.38
IPO DateFeb 13, 2007Option/ShortYes / YesEPS/Sales Surpr.-7.27% -Net Debt/EBITDA-0.09Volume3,092,642Change1.54%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedRoth CapitalBuy$43 → $38
Mar-13-26ReiteratedCantor FitzgeraldOverweight$62
Dec-15-25ReiteratedUBS$21 → $50
Dec-10-25ReiteratedPiper SandlerOverweight$20 → $45
Dec-08-25ReiteratedOppenheimerOutperform$43 → $54
Dec-04-25ReiteratedMaxim GroupBuy$25 → $50
Dec-03-25ReiteratedIndustrial Alliance Securities$16 → $48
Dec-03-25ReiteratedH.C. WainwrightBuy$24 → $60
Jul-11-25ReiteratedPiper Sandler$43 → $20
Jul-11-25ReiteratedH.C. WainwrightBuy$77 → $24
Latest News
Jun-18-26
Jun-18-2603:28PM
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study InitiationsSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue22022
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A51050
Gross Profit-280-28
Selling, General and Administrative Excl. Other142315
Research and Development518450
Other Operating Expense-511-50
Operating Income-43-108-43
Interest Expense030
Unusual Expense
———
Non-Operating Income (Expense)-2-6-2
Net Income Before Taxes-41-105-40
Income Taxes
000
Consolidated Net Income-41-105-40
Net Income From Continuing Operations-41-105-40
Net Income-41-105-40
EPS (Recurring)-1.20-2.26-1.15
EPS (Basic, Before Extraordinaries)-1.20-2.26-1.15
EPS (Diluted)-1.20-2.26-1.15
EBITDA-39-100-39
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
45.15——
Gross Margin-127.27—-127.27
Operating Margin-195.45—-195.45
Net Margin-186.36—-181.82
Shares Outstanding354635
Market Capitalization9931,328—
Operating Lease Expense
———
Insider Trading Volume
$30.11$26.58$23.06$19.54$16.01● Close Price0.00M0.84M1.68M2.52M3.35MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 18 '26Option Exercise1.396,0008,34011,223May 19 12:00 AM
Litvack FrankDirectorMay 13 '26Option Exercise1.397,87410,944133,776May 14 12:00 AM
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Sale31.7025,000792,5408,223May 04 12:00 AM
Krasney KarenEVP, GENERAL COUNSELMay 01 '26Option Exercise3.1850,000159,00056,261May 04 12:00 AM
Krasney KarenEVP, GENERAL COUNSELMay 01 '26Sale31.7025,000792,54830,547May 04 12:00 AM
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Option Exercise3.1850,000159,000116,980May 04 12:00 AM
Sabar Karimah EsDirectorApr 02 '26Option Exercise3.1815,05847,8847,529Apr 03 12:00 AM
Sabar Karimah EsDirectorApr 02 '26Sale32.007,529240,9280Apr 03 12:00 AM
Sabar Karimah EsDirectorApr 01 '26Option Exercise4.86107,470522,30453,735Apr 01 12:00 AM
Sabar Karimah EsDirectorApr 01 '26Sale31.0353,7351,667,2250Apr 01 12:00 AM
Sabar Karimah EsDirectorMar 31 '26Option Exercise4.86122,530595,49661,265Apr 01 12:00 AM
Krasney KarenEVP, GENERAL COUNSELMar 31 '26Option Exercise3.6150,000180,58481,261Apr 01 12:00 AM
Krasney KarenEVP, GENERAL COUNSELMar 31 '26Sale30.1225,000752,93530,547Apr 01 12:00 AM
Sabar Karimah EsDirectorMar 31 '26Sale30.1761,2651,848,2430Apr 01 12:00 AM
Bergmann AnthonyCHIEF FINANCIAL OFFICERMar 31 '26Option Exercise3.1850,000159,000141,980Apr 01 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR